Abstract
Donor T cell alloreactivity can be co-opted to deliver a graft-versus-tumor (GVT) response following blood or bone marrow transplantation (BMT). However, the major reason for treatment failure following BMT is tumor recurrence, suggesting a long-term failure of GVT immunity. In this study, we have considered the role of non-hematopoietic antigen in determining the fate of donor CD8 cells in a model of delayed DLI to partially MHC-mismatched chimeras, where antigen was either expressed ubiquitously or restricted to the hematopoietic compartment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
